| 1.33 -0.06 (-4.32%) | 01-09 13:15 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.75 | 1-year : | 2.04 |
| Resists | First : | 1.5 | Second : | 1.75 |
| Pivot price | 1.24 |
|||
| Supports | First : | 1.24 | Second : | 1.08 |
| MAs | MA(5) : | 1.29 |
MA(20) : | 1.27 |
| MA(100) : | 1.33  |
MA(250) : | 2.56 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 62 |
D(3) : | 52.4 |
| RSI | RSI(14): 54.5 |
|||
| 52-week | High : | 14.39 | Low : | 1.08 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ERNA ] has closed below upper band by 9.0%. Bollinger Bands are 37.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.4 - 1.41 | 1.41 - 1.41 |
| Low: | 1.19 - 1.19 | 1.19 - 1.2 |
| Close: | 1.38 - 1.39 | 1.39 - 1.4 |
Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of solid tumors and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-102, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025. Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Tue, 06 Jan 2026
Ernexa Therapeutics Advances Ovarian Cancer Treatment Toward First-in-Human Trial After FDA Meeting - Quiver Quantitative
Tue, 06 Jan 2026
Ernexa Therapeutics Announces Successful Pre-IND FDA - GlobeNewswire
Mon, 08 Dec 2025
Ernexa Therapeutics stock falls after ASH meeting presentation - Investing.com
Mon, 10 Nov 2025
Ernexa Therapeutics (Nasdaq: ERNA) sets H2 2026 Phase 1 in PROC; operating loss decreased - Stock Titan
Thu, 06 Nov 2025
Ernexa Therapeutics Announces Partnership with Cellipont Bioservices to Advance ERNA-101 for Ovarian Cancer Treatment - Quiver Quantitative
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 8 (M) |
| Held by Insiders | 2.68e+006 (%) |
| Held by Institutions | 66.6 (%) |
| Shares Short | 164 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -9.85e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -992 % |
| Return on Assets (ttm) | 200 % |
| Return on Equity (ttm) | -89.3 % |
| Qtrly Rev. Growth | 1000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 148.8 |
| Qtrly Earnings Growth | 56.3 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -9 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 19.79 |
| Dividend | 0 |
| Forward Dividend | 118470 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|